Compare Monster Beverage Corp (MNST) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Merck & Co., Inc. — how do they compare? Monster Beverage Corp trades at $45.33 (market cap $89.20B), while Merck & Co., Inc. trades at $131.98 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 3.6× Monster Beverage Corp's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals.
| MNST | MRK | |
|---|---|---|
Market Cap | $89.20B | $321.77B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $131.84 |
52-Week Low | $30.86 | $77.60 |
Enterprise Value | $87.49B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $45.69, up 1.13% today. The stock shows strong fundamentals with Q2 2026 EPS of $0.60 beating estimates, driven by 20% revenue growth and a 23.08% net income margin. A 2-for-1 stock split occurred on August 11, 2026. However, technical indicators signal a bearish trend, with the current price below key resistance levels. Analyst consensus is bullish with a $51.14 price target, but high valuation ratios like a P/E of 42.16 pose risks.
Outlook: MNST's international expansion and earnings beats support growth, but stretched valuations and bearish technicals suggest near-term volatility. Investment opportunity lies in sustained profit margins, while risks include competitive pressures and premium pricing sensitivity.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
